CBIS LATEST NEWS.

2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009


Inspired by the Upcoming CNN Special Report, Weed: Pot Vs. Pills, by Dr. Sanjay Gupta, Cannabis Science Announces its ‘Cannabis Science to End Opioid Deaths Campaign’

Inspired by the Upcoming CNN Special Report, Weed: Pot Vs. Pills, by Dr. Sanjay Gupta, Cannabis Science Announces its ‘Cannabis Science to End Opioid Deaths Campaign’

Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, and its partner, Cali RX, are pleased to announce the CBIS Cali RX location at 14006 Ventura Boulevard, Sherman Oaks, California 91423 will launch the ‘Cannabis Science to End Opioids Deaths Now Campaign!’ to address the serious opioid issue. Presented as another ‘iCannabinoid, We the People Campaign!, this new initiative will be presented at the Company’s upcoming Educational Expo at the new CBIS Cali RX location on Ventura Boulevard. 

 “We believe we need to take the opioid fight to the streets!” stated Mr. Raymond C. Dabney, Cannabis Science’s President, CEO, and Co-founder. “We will be discussing the Company’s major initiatives, the newest ‘Cannabis Science to End Opioids Deaths Now Campaign!’ presented as another ‘iCannabinoid, We the People Campaign!’ We will also discuss Cannabis Science’s drug-development consortium, and iCannabinoid, the Company’s social media and educational interactive online platform. We will bring in special guests to discuss scholarship programs and special opportunities available through Cannabis Science’s educational partners, including American States University, American Heritage University School of Law, and the Raymond C. Dabney University. This opioid fight just got serious!”

Cannabis Science will implement its ‘Cannabis Science to End Opioids Deaths Now Campaign!’  This will be another ‘iCannabinoid, We the People Campaign’! All CBIS pharmacy locations will implement special programs to educate the people and help eradicate opioid deaths by replacing  opioids with Cannabinoids, pills, extracts, tinctures, sprays, inhalers, and many more options that all have serious potential to end opioid additions. “It has been known that Cannabis is used as a ‘Gateway out’ of opioid addiction. This is not new,” stated Mr. Dabney. “Why aren’t the people educated?  This is where we can step up our game and help educate on the potential benefits of cannabinoids. Sign up in iCannabinoid and set up your own ‘Action Group’ or join an existing ‘End Opioid Deaths’ Action Group, or come on down to our Ventura Boulevard location and we’ll come up with some ideas and solutions for you to try. We the people can make a change. One saved life at a time is more than enough to motivate me to start making a difference right now!” concluded Mr. Dabney.

A CNN SPECIAL REPORT: Dr. Sanjay Gupta WEED 4: Pot Vs Pills

Please click here to view the whole report:

http://cnnpressroom.blogs.cnn.com/2018/04/18/a-cnn-special-report-dr-sanjay-gupta-weed-4-pot-vs-pills/

“Politicians promise to lead the country out of the worst drug crisis in its history, but opioid abuse continues to kill Americans in record numbers.  Are our leaders ignoring a lifesaving solution?  Over 115 Americans die every day from opioid overdoses, more than those killed in car accidents, from breast cancer or even guns.  Nearly 2.5 million Americans struggle with opioid addiction, and though controversial, some people believe a potentially lifesaving solution may lie in medical marijuana.  In the fourth installment of his groundbreaking series, CNN chief medical correspondent Dr. Sanjay Gupta takes an in-depth look at marijuana’s potential as both an alternative to opioids in treating pain and in ending opioid addiction.  WEED 4:  POT VERSUS PILLS will air on CNN, Sunday, April 29th at 8pm ET.

WEED 4: POT VS PILLS will stream live for subscribers on Sunday April 29th via CNNgo (at CNN.com/go and via CNNgo apps for Apple TV, Roku, Amazon Fire, Samsung Smart TV and Android TV) and on the CNN mobile apps for iOS and Android. The documentary will also be available the day after the broadcast premiere on demand via cable/satellite systems, CNNgo platforms and CNN mobile apps.  Weed 1-3 is now also available for subscribers via CNNgo (at CNN.com/go and via CNNgo apps for Apple TV, Roku, Amazon Fire, Samsung Smart TV and Android TV) and on the CNN mobile apps for iOS and Android.”

The CBIS Cali RX location on Ventura Boulevard will benefit from being located on one of the primary east-to-west thoroughfares in the San Fernando Valley. Ventura Boulevard is one of the oldest routes in the San Fernando Valley, as it was originally a part of the El Camino Real (the trail between Spanish missions). Historically, local and small shops have concentrated and thrived along Ventura Boulevard. 

Cannabis Science encourages its customers to inquire about iCannabinoid, the Company’s online, high-tech social platform, at all locations. Cannabis Science’s aim is to have a fully-integrated community, by providing the experience of brick-and-mortar locations, as well as an online community for sharing experiences with medical marijuana and learning about the industry.

SIGN UP NOW! Build and your own ‘Cannabis Science to End Opioids Deaths Now Campaign!” as another “iCannabinoid, We the People Campaign’! or join-in other Action Groups to help make a difference now one person at a time. 

Connect, Learn, and Share;  http://icannabinoid.com/

About Cannabis Science, Inc. 


Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements


This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.